Institutional shares held 0
0 calls
0 puts
Total value of holdings $0
$0 calls
$0 puts
Market Cap N/A
Institutional ownership N/A
# of Institutions 1

Quarterly Institutional Activity in MTCR

Shares Bought
Shares Sold
View Transactions

Latest Institutional Activity in MTCR

Top Purchases

Q3 2024
Concourse Financial Group Securities, Inc. Shares Held: 0 ($0)
Q1 2023
Jbf Capital, Inc. Shares Held: 1.95M ($0)
Q4 2022
Bml Capital Management, LLC Shares Held: 6.17M ($0)
Q4 2022
Tang Capital Management LLC Shares Held: 4.25M ($0)
Q4 2022
Bank Of New York Mellon Corp Shares Held: 204K ($0)

Top Sells

Q1 2023
State Street Corp Shares Held: 0 ($0)
Q1 2023
Tudor Investment Corp Et Al Shares Held: 239K ($0)
Q4 2022
Jane Street Group, LLC Shares Held: 88.4K ($0)
Q4 2022
Ubs Group Ag Shares Held: 4.78K ($0)
Q4 2022
Susquehanna International Group, LLP Shares Held: 24.1K ($0)

About MTCR

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.


Insider Transactions at MTCR

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on MTCR

Follow Metacrine, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MTCR shares.

Notify only if

Insider Trading

Get notified when an Metacrine, Inc. insider buys or sells MTCR shares.

Notify only if

News

Receive news related to Metacrine, Inc.

Track Activities on MTCR